Ally Bridge Group, a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK: 1302), a medical device company in China, to focus on investing in the world’s leading medtech companies.
The partnership aims to help them to accelerate their market entry and commercialization in China.
The ABG-LifeTech partnership encompasses three key components:
1) ABG and LifeTech commit to being the preferred partners to each other for global medtech investments and operations;
2) LifeTech commits to invest in ABG’s funds, which has already been — and will continue to be — investing in some of the world’s most innovative medtech companies;
3) ABG and LifeTech commit to setting up a joint investment fund (subject to regulatory approval) dedicated to investing in innovative medical technologies globally and expediting their development and commercialization in China by leveraging favorable China policies and LifeTech’s proven capabilities.